Etoposide has 10 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyclosporine, Pentostatin, Aprepitant. Patients taking Etoposide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 10
- Major
- 2
- Moderate
- 6
- Minor
- 2
Major (2)
- Etoposide + Cyclosporine— High-dose cyclosporin A (concentrations >2000 ng/mL) increases etoposide exposure by 80% and decreases total body cleara…
- Etoposide + Pentostatin— Acute pulmonary edema and hypotension leading to death reported when used with pentostatin in combination chemotherapy r…
Moderate (6)
- Etoposide + Aprepitant— Increased etoposide exposure possible; no dosage adjustment needed but monitor for adverse reactions.
- Etoposide + Fosaprepitant— Increased exposure of chemotherapeutic agent; no dosage adjustment needed but monitor for adverse effects.
- Etoposide + Fosaprepitant Dimeglumine— Increased exposure possible via CYP3A4 inhibition, but no dosage adjustment needed. Monitor for adverse reactions.
- Etoposide + Gadobenate Dimeglumine— MultiHance may compete for MOAT transporter and prolong systemic exposure of etoposide.
- Etoposide + Netupitant And Palonosetron— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Etoposide + Warfarin— Co-administration of etoposide with warfarin can result in elevated international normalized ratio (INR). Monitor INR mo…
Minor (2)
- Etoposide + Ondansetron— Etoposide does not affect the pharmacokinetics of ondansetron.
- Etoposide + Ondansetron Hydrochloride— No effect on ondansetron pharmacokinetics observed in humans.